---
schema_version: "secwatch.filing_event.v1"
accession: "0001517022-24-000057"
form_type: "8-K"
ticker: "AKBA"
cik: "0001517022"
company_name: "Akebia Therapeutics, Inc."
filed_at: "2024-06-10T23:59:59+00:00"
generated_at: "2026-06-01T05:17:11.978274+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Akebia Therapeutics shareholders reject proposal to increase share reserve by 9.8M shares

## Summary
- Three Class I directors elected: Ronald E. Frieson, Steven C. Gilman, Ph.D., Cynthia Smith.
- Proposal to increase 2023 Stock Incentive Plan by 9.8M shares failed (52.8M against vs 45.2M for).
- Advisory say-on-pay compensation approved narrowly (48.9M for, 47.4M against).
- Ratification of Ernst & Young as independent auditor for FY 2024 approved (120.2M for).

## SEC filing metadata
- accession: 0001517022-24-000057
- form_type: 8-K
- ticker: AKBA
- cik: 0001517022
- company_name: Akebia Therapeutics, Inc.
- filed_at: 2024-06-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517022/000151702224000057/0001517022-24-000057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517022/000151702224000057/akba-20241006cfo.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001517022-24-000057
- JSON: https://secwatch.observer/filing/0001517022-24-000057.json
- Plain text: https://secwatch.observer/filing/0001517022-24-000057.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.